Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks

Simply Wall St.

Aug 19

Ultragenyx Pharmaceutical stock has retreated sharply over the past few years, yet current valuation checks suggest the shares are not a clear bargain. Recent price weakness, including a fall over the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2660342910"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660342910\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660342910?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-19 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660342910","market":"nz","top_or_hot":-1,"title":"Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks","media":"Simply Wall St.","content":"<div>\n<p>Ultragenyx Pharmaceutical stock has retreated sharply over the past few years, yet current valuation checks suggest the shares are not a clear bargain. Recent price weakness, including a fall over the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-rare-stock-could-stay-fully-priced-on-setrusumab\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-19 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-rare-stock-could-stay-fully-priced-on-setrusumab><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ultragenyx Pharmaceutical stock has retreated sharply over the past few years, yet current valuation checks suggest the shares are not a clear bargain. Recent price weakness, including a fall over the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-rare-stock-could-stay-fully-priced-on-setrusumab\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-rare-stock-could-stay-fully-priced-on-setrusumab","article_id":"2660342910","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-rare-stock-could-stay-fully-priced-on-setrusumab","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660342910","pubTimestamp":1787146406,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ultragenyx Pharmaceutical stock has retreated sharply over the past few years, yet current valuation checks suggest the shares are not a clear bargain. Recent price weakness, including a fall over the past month, now meets a mixed verdict from the broader valuation framework.\n\nUltragenyx Pharmaceutical has declined 70.8% over the past 5 years, which may lead some investors to question whether sentiment has become too pessimistic or if the earlier pricing was simply too optimistic.\nProgress...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RARE":"Ultragenyx Pharmaceutical Inc","CDIG":"City Different Investments Global Equity ETF","TSPA":"T. Rowe Price U.S. Equity Research ETF","TACU":"T. Rowe Price Active Core U.S. Equity ETF"},"translate_title":"在Setrusumab监管谈判中，Ultragenyx（稀有）股票可能保持全价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDIG":0.6,"TSPA":0.6,"RARE":1.5,"TACU":0.6},"content_text":"Ultragenyx Pharmaceutical stock has retreated sharply over the past few years, yet current valuation checks suggest the shares are not a clear bargain. Recent price weakness, including a fall over the past month, now meets a mixed verdict from the broader valuation framework.  Ultragenyx Pharmaceutical has declined 70.8% over the past 5 years, which may lead some investors to question whether sentiment has become too pessimistic or if the earlier pricing was simply too optimistic. Progress with setrusumab in osteogenesis imperfecta alongside partner Mereo BioPharma can support expectations for future revenue, while regulatory outcomes and execution on this program may also limit how much value investors are willing to ascribe today. With a value score of 4 out of 6, Ultragenyx Pharmaceutical presents a mixed picture rather than a clear bargain or clear overvaluation.  The stock's next move may depend on whether the recent share price decline has already captured the key risks around Ultragenyx Pharmaceutical, or if the current valuation still builds in expectations that are too optimistic. Find out why Ultragenyx Pharmaceutical's -12.5% return over the last year is lagging behind its peers. AdvertisementIs Ultragenyx Pharmaceutical Getting Expensive on Sales? P/S is often a useful check for Ultragenyx Pharmaceutical because revenue can be more stable than earnings for companies that are still investing heavily and reporting losses. Ultragenyx Pharmaceutical currently trades on a P/S multiple of 3.5x. This is below the Biotechs industry average P/S of 11.1x and also below the peer average of 7.9x. However, a more tailored fair P/S ratio that takes into account Ultragenyx Pharmaceutical's business profile and risk level sits lower at 2.6x. That leaves the current share price at a premium to this fair multiple, even if it screens below broad sector benchmarks. Despite ongoing attention on setrusumab following the recent Mereo BioPharma update, the market is still pricing Ultragenyx Pharmaceutical above what the fair P/S model suggests would be in line with its characteristics. The gap is not extreme, but it does point to investors already assigning a degree of optimism to future revenue delivery at today's price. On this P/S check, Ultragenyx Pharmaceutical stock screens as overvalued relative to the fair multiple implied by its own fundamentals. NasdaqGS:RARE P/S Ratio as at Aug 2026 See what the numbers say about this price — find out in our valuation breakdown. The Ultragenyx Pharmaceutical Narrative: What Would Justify Today's Price? Simply Wall St Narratives pick up where this Ultragenyx Pharmaceutical valuation puzzle leaves off. They explain which assumptions on Ultragenyx Pharmaceutical's future growth, margins and earnings would need to hold for the stock to be valued significantly above or below the current price. Each Narrative treats fair value as a thesis about the business that you can observe and assess over time. These Narratives are available on Simply Wall St's Community page. One of the top community narratives on Ultragenyx Pharmaceutical: roughly fairly valued \"Ultragenyx has phenomenal science, but its commercial execution is a cash-incinerating treadmill, and at these multiples, the safety margin for a 2027 BEP inflection is practically non-existent.\" Read one of the top narratives on Ultragenyx Pharmaceutical Do you think there's more to the story for Ultragenyx Pharmaceutical? Head over to our Community to see what others are saying! The Bottom Line For Ultragenyx Pharmaceutical, the key takeaway is that the stock screens as mildly overvalued on the current P/S workup, even though broader valuation checks look mixed rather than extreme. The recent weakness in the share price has not yet removed the premium to the tailored fair multiple, which suggests investors are still paying up for the potential of setrusumab and the wider pipeline. The debate from here is whether execution on those programs can match the optimism already embedded in the multiple, or whether expectations need to cool further before the risk and reward feel better balanced.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}